Imagine treating a disease based on a map that suddenly changes. This study examined 436 samples from patients with primary and metastatic breast cancer to see if the cancer's targets shifted. Many tumors did change, losing the hormone receptors or HER2 proteins that guide their treatment. When these targets disappeared, patients had a median survival of 70 to 95 months depending on the specific change. In contrast, patients whose tumors kept or gained these targets lived longer.
The research involved looking at how the cancer evolved in the body. About 33% of tumors showed a mismatch between the original and later samples. This was especially common in liver metastases, where 59% of cases showed a change in HER2 status. The study did not report specific safety issues or side effects, focusing instead on how these changes affected how long patients lived.
The main takeaway is that the cancer's identity is not always fixed. Losing the targets doctors rely on for endocrine therapy, chemotherapy, or targeted therapy makes the disease harder to control. Reassessing the cancer's status in later stages is essential to optimize treatment and improve outcomes for real people facing this illness.
